Patents by Inventor Joshua Epstein
Joshua Epstein has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11779156Abstract: A beverage container assembly including a cup and a lid. The cup includes an outer wall and an inner wall. The cup may have a double truncated cone shape. The lid includes a spout for drinking a beverage held in the cup and a number of holes that allow aroma to escape from the cup. The cup includes an internal protrusion that aids in mixing the beverage.Type: GrantFiled: February 12, 2021Date of Patent: October 10, 2023Assignee: SPROGO LLCInventor: Joshua Epstein
-
Publication number: 20220257036Abstract: A beverage container assembly including a cup and a lid. The cup includes an outer wall and an inner wall. The cup may have a double truncated cone shape. The lid includes a spout for drinking a beverage held in the cup and a number of holes that allow aroma to escape from the cup. The cup includes an internal protrusion that aids in mixing the beverage.Type: ApplicationFiled: February 12, 2021Publication date: August 18, 2022Inventor: Joshua Epstein
-
Publication number: 20210204991Abstract: A surgical screw that is self-countersinking, self-tapping/fluted, self-drilling, and having a knurled shank designed for one step insertion. The screw has a stepped driving portion.Type: ApplicationFiled: January 8, 2021Publication date: July 8, 2021Inventors: Joshua Epstein, Derrick Roland
-
Publication number: 20200392587Abstract: The invention provides, inter alia, methods of prognosing a subject with, or suspected of having, multiple myeloma. In certain embodiments, the methods entail testing the gene expression levels of enolase 1 (ENO1), fatty acid binding protein 5 (FABP5), thyroid hormone receptor interactor 13 (TRIP13), transgelin 2 (TAGLN2), and replication factor C (activator 1) 4 (RFC4) in a biological sample isolated from the subject. The invention also provides methods of treatment for multiple myeloma, as well as kits, oligonucleotides, and systems for performing the methods provided by the invention.Type: ApplicationFiled: August 24, 2020Publication date: December 17, 2020Applicant: BioVentures, LLCInventors: Bart BARLOGIE, Pingping QU, Christoph HEUCK, Joshua EPSTEIN
-
Patent number: 10752956Abstract: The invention provides, inter alia, methods of prognosing a subject with, or suspected of having, multiple myeloma. In certain embodiments, the methods entail testing the gene expression levels of enolase 1 (ENO1), fatty acid binding protein 5 (FABP5), thyroid hormone receptor interactor 13 (TRIP13), transgelin 2 (TAGLN2), and replication factor C (activator 1) 4 (RFC4) in a biological sample isolated from the subject. The invention also provides methods of treatment for multiple myeloma, as well as kits, oligonucleotides, and systems for performing the methods provided by the invention.Type: GrantFiled: November 17, 2017Date of Patent: August 25, 2020Assignee: BioVentures, LLCInventors: Bart Barlogie, Pingping Qu, Christoph Heuck, Joshua Epstein
-
Publication number: 20180171414Abstract: The invention provides, inter alia, methods of prognosing a subject with, or suspected of having, multiple myeloma. In certain embodiments, the methods entail testing the gene expression levels of enolase 1 (ENO1), fatty acid binding protein 5 (FABP5), thyroid hormone receptor interactor 13 (TRIP13), transgelin 2 (TAGLN2), and replication factor C (activator 1) 4 (RFC4) in a biological sample isolated from the subject. The invention also provides methods of treatment for multiple myeloma, as well as kits, oligonucleotides, and systems for performing the methods provided by the invention.Type: ApplicationFiled: November 17, 2017Publication date: June 21, 2018Applicant: BioVentures, LLCInventors: Bart Barlogie, Pingping Qu, Christoph Heuck, Joshua Epstein
-
Patent number: 9822419Abstract: The invention provides, inter alia, methods of prognosing a subject with, or suspected of having, multiple myeloma. In certain embodiments, the methods entail testing the gene expression levels of enolase 1 (ENO1), fatty acid binding protein 5 (FABP5), thyroid hormone receptor interactor 13 (TRIP 13), transgelin 2 (TAGLN2), and replication factor C (activator 1) 4 (RFC4) in a biological sample isolated from the subject. The invention also provides methods of treatment for multiple myeloma, as well as kits, oligonucleotides, and systems for performing the methods provided by the invention.Type: GrantFiled: May 19, 2014Date of Patent: November 21, 2017Assignee: BioVentures, LLCInventors: Bart Barlogie, Pingping Qu, Christoph Heuck, Joshua Epstein
-
Publication number: 20160102362Abstract: The invention provides, inter alia, methods of prognosing a subject with, or suspected of having, multiple myeloma. In certain embodiments, the methods entail testing the gene expression levels of enolase 1 (ENO1), fatty acid binding protein 5 (FABP5), thyroid hormone receptor interactor 13 (TRIP 13), transgelin 2 (TAGLN2), and replication factor C (activator 1) 4 (RFC4) in a biological sample isolated from the subject. The invention also provides methods of treatment for multiple myeloma, as well as kits, oligonucleotides, and systems for performing the methods provided by the invention.Type: ApplicationFiled: May 19, 2014Publication date: April 14, 2016Inventors: Bart BARLOGIE, Pingping QU, Christoph HEUCK, Joshua EPSTEIN
-
Publication number: 20140079813Abstract: Provided are methods, systems and kits for predicting post-relapse survival of a cancer patient and for identifying cancer genes predictive of the post-relapse survival of the patient. Values representing gene expression levels of a group of genes associated with survival of the cancer cells are determined using gene expression profiling platforms and a plurality of probe sets that hybridize to one or more of the genes in the group. A predictive model establishes a predictive value based on the weighted contribution of each gene associated with survival of the cancer cells to risk of death for the cancer patient and imports expression values of the genes in the group that is indicative of a risk of death for the relapsed patient.Type: ApplicationFiled: April 27, 2012Publication date: March 20, 2014Inventors: Joshua Epstein, Shmuel Yaccoby, John D. Shaughnessy, JR., Barthel Barlogie, Igor Entin
-
Patent number: 8318297Abstract: In one aspect, the present invention relates to a synthetic nanostructure. In one embodiment, the synthetic nanostructure has a top region substantially comprising titanate nanowires, a middle region substantially comprising titanate nanoparticles and titanate nanowires, and a bottom region substantially comprising titanium, wherein some of the titanate nanowires of the top region are extending into the middle region, wherein the middle region is between the top region and the bottom region, and wherein some of the titanate nanowires of the top region are substantially perpendicular to the bottom surface of the titanium substrate. At least some of the titanate nanowires in the top region form 3D macroporous scaffolds with interconnected macropores.Type: GrantFiled: June 25, 2008Date of Patent: November 27, 2012Assignee: Board of Trustees of the University of ArkansasInventors: Z. Ryan Tian, Joshua Epstein
-
Publication number: 20110269638Abstract: Provided are methods, systems and kits for predicting post-relapse survival of a cancer patient and for identifying cancer genes predictive of the post-relapse survival of the patient. Values representing gene expression levels of a group of genes associated with survival of the cancer cells are determined using gene expression profiling platforms and a plurality of probe sets that hybridize to one or more of the genes in the group. A predictive model establishes a predictive value based on the weighted contribution of each gene associated with survival of the cancer cells to risk of death for the cancer patient and imports expression values of the genes in the group that is indicative of a risk of death for the relapsed patient.Type: ApplicationFiled: April 29, 2011Publication date: November 3, 2011Inventors: Joshua Epstein, Shmuel Yaccoby, John D. Shaughnessy, JR., Barthel Barlogie, Igor Entin
-
Publication number: 20080318044Abstract: In one aspect, the present invention relates to a synthetic nanostructure. In one embodiment, the synthetic nanostructure has a top region substantially comprising titanate nanowires, a middle region substantially comprising titanate nanoparticles and titanate nanowires, and a bottom region substantially comprising titanium, wherein some of the titanate nanowires of the top region are extending into the middle region, wherein the middle region is between the top region and the bottom region, and wherein some of the titanate nanowires of the top region are substantially perpendicular to the bottom surface of the titanium substrate. At least some of the titanate nanowires in the top region form 3D macroporous scaffolds with interconnected macropores.Type: ApplicationFiled: June 25, 2008Publication date: December 25, 2008Applicant: BOARD OF TRUSTEES OF THE UNIVERSITY OF ARKANSASInventors: Z. Ryan TIAN, Joshua EPSTEIN
-
Patent number: D1022598Type: GrantFiled: February 12, 2021Date of Patent: April 16, 2024Assignee: SPROGO LLCInventor: Joshua Epstein